ALGS FY 2021 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$4M100.0% margin

Operating Income

-$128M-2943.8% margin

Net Income

-$128M-2944.1% margin

EPS (Diluted)

$-3.22

Cash Flow

Operating Cash Flow

-$116M

Free Cash Flow

-$117M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$235M

Total Liabilities

$51M

Stockholders' Equity

$185M

Cash & Equivalents

$187M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$4M	-$3M	+231.1%
Operating Income	-$128M	-$98M	-31.2%
Net Income	-$128M	-$109M	-18.2%